<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17456" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Amikacin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sizar</surname>
            <given-names>Omeed</given-names>
          </name>
          <aff>St. Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rahman</surname>
            <given-names>Sajedur</given-names>
          </name>
          <aff>St. John's Episcopal Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sundareshan</surname>
            <given-names>Vidya</given-names>
          </name>
          <aff>SIU School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Omeed Sizar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sajedur Rahman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vidya Sundareshan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17456.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Amikacin is an antimicrobial with activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. It also has excellent activity against most aerobic gram-negative bacilli from the Enterobacteriaceae family, including Nocardia sp. and some Mycobacterium spp. (M. avium-intracellulare, M. chelonae, and M. fortuitum). Unlike gentamicin, amikacin does not provide synergistic activity against Enterococcus faecium when combined with beta-lactam antibiotics. This activity covers amikacin, its mechanism, activity spectrum, and its place in an infectious disease regimen. Members of the interprofessional team need to review its indications, coverage, contraindications, and adverse event profile to optimally manage patients with infectious disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the mechanism of action of amikacin.</p></list-item><list-item><p>Identify the bacterial coverage and indications for amikacin.</p></list-item><list-item><p>Review the adverse events of amikacin, including proper monitoring procedures.</p></list-item><list-item><p>Explain amikacin's place in infectious disease management as it pertains to improving care coordination amongst the interprofessional team and in the context of antimicrobial stewardship.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17456&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17456">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17456.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Amikacin's niche is because it also has activity against more resistant gram-negative bacilli such as <italic toggle="yes">Acinetobacter baumanii</italic> and <italic toggle="yes">Pseudomonas aeruginosa</italic>. It also has excellent activity against most aerobic gram-negative bacilli from the <italic toggle="yes">Enterobacteriaceae</italic> family, including Nocardia sp. and some Mycobacterium spp. (<italic toggle="yes">M. avium-intracellulare</italic>, <italic toggle="yes">M. chelonae</italic>, and <italic toggle="yes">M. fortuitum</italic>). Unlike gentamicin, amikacin does not provide synergistic activity against Enterococcus faecium when combined with beta-lactam antibiotics.<xref ref-type="bibr" rid="article-17456.r1">[1]</xref><xref ref-type="bibr" rid="article-17456.r2">[2]</xref><xref ref-type="bibr" rid="article-17456.r3">[3]</xref></p>
        <p>Amikacin is rarely used alone and often combined with other antimicrobials.</p>
        <p>
<bold>Indications Include</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Hospital-acquired/ventilator-associated/healthcare-associated pneumonia</p>
          </list-item>
          <list-item>
            <p>Endophthalmitis, bacterial (intravitreal injection, OFF LABEL)</p>
          </list-item>
          <list-item>
            <p>Meningitis (IV) or (intrathecal/intraventricular, OFF LABEL)</p>
          </list-item>
          <list-item>
            <p>Wound infections caused by susceptible organisms</p>
          </list-item>
          <list-item>
            <p>Urinary tract infections (Generally only if caused by resistant organisms, OFF LABEL)</p>
          </list-item>
          <list-item>
            <p>Gram-negative bacteremia/sepsis (OFF LABEL)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17456.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Amikacin binds to the 30 S bacterial ribosome subunit, resulting in interference with a reading of the genetic code and inhibition of protein synthesis, e.g., elicits premature protein termination and incorporation of incorrect amino acid.&#x000a0; Amikacin, as well as the rest of the aminoglycosides, are generally&#x000a0;bacteriocidal and probably have an additional mechanism of action, which as yet remains undetermined. Aminoglycosides demonstrate bacterial killing that is concentration-dependent and also have a post-antibiotic effect.</p>
        <p>Amikacin, when combined with penicillins, can have an additive effect on specific microorganisms.</p>
        <p>Amikacin, when combined with carbapenems, can have a synergistic effect against some gram-positive organisms.</p>
        <p>Amikacin may retain activity against tobramycin- and gentamicin-resistant strains because of reduced inactivation by bacterial acetylase, adenylase, and phosphorylase. Thus, its routine clinical use should be reserved for difficult to treat serious nosocomial infections.<xref ref-type="bibr" rid="article-17456.r4">[4]</xref></p>
      </sec>
      <sec id="article-17456.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Amikacin can be administered parenterally or via nebulization. There is no oral formulation of the drug available because the drug is not absorbed from the gastrointestinal tract. Amikacin can be administered intramuscularly when intravenous access is not available. In some patients with meningitis, it can be administered intrathecally and reaches high concentrations in the cerebrospinal fluid immediately.<xref ref-type="bibr" rid="article-17456.r5">[5]</xref><xref ref-type="bibr" rid="article-17456.r6">[6]</xref><xref ref-type="bibr" rid="article-17456.r7">[7]</xref></p>
        <p>
<bold>Dosing based on weight (Kg):</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Underweight or nonobese: dose on ACTUAL body weight (ABW)</p>
          </list-item>
          <list-item>
            <p>Obese (ABW/IBW* &#x0003e; or = to 1.25): dose on DOSING body weight (DBW= IBW + 0.4(ABW - IBW)</p>
          </list-item>
        </list>
        <p>
<bold>Adult Dosing:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Conventional Dosing:</bold> 5mg/kg IV every 8 hours - the elderly often require only a 12 hr dosing interval</p>
          </list-item>
          <list-item>
            <p>
<bold>Adjustment for renal impairment (assuming every 8-hr dosing)</bold>
</p>
          </list-item>
        </list>
        <p>Greater than 50 mL/min (CrCL): no adjustment</p>
        <p>30 to 50 mL/min: every 12 to 18 hrs</p>
        <p>10 to 29 mL/min: every 18 to 24 hr</p>
        <p>Less than 10 mL/min: dose based on plasma concentrations or consult a pharmacist.</p>
        <p>
<bold>Once Daily Dosing: </bold>
</p>
        <p>
<italic toggle="yes">Not to be used in patients with ascites, over 20% BSA burns, pregnant patients, or patients on dialysis. (Use conventional dosing or consult a pharmacist.)</italic>
</p>
        <p>15 mg/kg per dose once daily</p>
        <p>
<bold>Adjustment for renal impairment: </bold>
</p>
        <p>60 mL/min (CrCL) and above: every 24 hours</p>
        <p>40 to 59 mL/min: every 36 hours</p>
        <p>30 to 39 mL/min: every 48 hours</p>
        <p>Less than 30mL/min: Use conventional dosing method</p>
        <p><bold>Intravitreal:</bold> 0.4 mg/0.1 mL of normal saline (preservative-free formulation, OFF LABEL)</p>
        <p><bold>Intrathecal/intraventricular:</bold> 5 to 50 mg/day, usual dose is 30 mg (preservative-free formulation, OFF LABEL)</p>
        <p>*IBW: Ideal body weight, ABW: Actual body weight, DBW: Dosing body weight, CrCL: creatinine clearance (not eGFR)</p>
        <p>There is also liposomal amikacin undergoing clinical trials to treat respiratory infections in patients with cystic fibrosis and bronchiectasis. In the trials, the liposomal dosage form is being used to treat nontuberculous bacteria and Pseudomonas aeruginosa. Liposomal amikacin is FDA indicated for the treatment of <italic toggle="yes">Mycobacterium avium</italic> complex (MAC), which is inhaled using a nebulizer for 14 to 20 minutes.</p>
        <p>Special Populations</p>
        <p>Amikacin use requires great caution in the elderly population who tend to&#x000a0;have decreased renal function. Also, young children do not have a fully developed renal system, and hence smaller doses are necessary.</p>
      </sec>
      <sec id="article-17456.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Major Adverse Effects</bold>
</p>
        <p>Nephrotoxicity is the most common, occurring in 1% to 10% of patients. The nephrotoxicity is reversible if detected early and the drug discontinued. Renal damage is more likely to occur in dehydrated patients, have a low glomerular filtration rate, have diabetes, sepsis, fever, or are on NSAIDs.<xref ref-type="bibr" rid="article-17456.r8">[8]</xref></p>
        <p>Ototoxicity, vestibular, and auditory (4% to 6%) can occur when using high doses. The patient may complain of loss of balance and hearing loss, which can be permanent if drug therapy continues for prolonged periods. The ototoxicity is believed to be due to oxidative free radicals, which damage the hair cells in the cochlea. Many hospitals now routinely monitor hearing before, during, and after therapy in infants.</p>
        <p>Neuromuscular blockade is less common.</p>
        <p>
<bold>Minor Effects</bold>
</p>
        <p>Increase in BUN/Cr (5% to 25%), drug fever, and rash (less common).</p>
        <p>Neurotoxicity may present in some patients with paresthesias, tingling, and numbness.&#x000a0;</p>
      </sec>
      <sec id="article-17456.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Patients may demonstrate hypersensitivity to amikacin, other aminoglycosides, or any component of the drug formulation.</p>
        <p>Amikacin can pass through breast milk and the placenta. Hence it is not recommended in pregnant women as the drug may cause congenital deafness in the infant. Even though only small amounts pass into breast milk, experts do not recommend breastfeeding while on amikacin.</p>
        <p>In general, amikacin is not used in infants. Further, since infants and small children tend to&#x000a0;have a large volume of distribution, the drug remains in the systemic circulation for prolonged periods.</p>
        <p>Clinicians should not use amikacin in combination with other drugs that have the potential to cause renal and auditory toxicity. The list of medications that should be avoided includes amphotericin B, acyclovir, capreomycin, bacitracin, vancomycin, and cisplatin. Also, amikacin should not be used in patients receiving neuromuscular blockers because it can prolong muscle paralysis and weakness.<xref ref-type="bibr" rid="article-17456.r4">[4]</xref></p>
      </sec>
      <sec id="article-17456.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Monitor renal function (BUN/Cr every 1 to 2 days based on the stability of renal function), Ins and Outs (daily), hearing parameters (baseline and weekly audiograms), symptoms of vertigo/dizziness (daily), peak concentrations (conventional dosing, no need in once-daily dosing) and trough concentrations (both conventional and once-daily dosing, repeat every 2 to 3 days and prolong if plasma concentrations are stable.<xref ref-type="bibr" rid="article-17456.r9">[9]</xref></p>
        <p>
<bold>Conventional Dosing Concentrations</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Obtain peak concentrations (1 hr after the start of a 30 min infusion) after 24 hrs or four half-lives</p>
          </list-item>
          <list-item>
            <p>Obtain trough concentrations (30 min before the next scheduled dose) again after</p>
          </list-item>
        </list>
        <p>
<bold>Goal Concentrations</bold>
</p>
        <p>Peak:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serious infection: 20 to 25 mg/dL</p>
          </list-item>
          <list-item>
            <p>Life-Threatening infection: 25 to 30 mg/dL</p>
          </list-item>
        </list>
        <p>Trough:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serious infection: 1 to 4 mg/dL</p>
          </list-item>
          <list-item>
            <p>Life-Threatening infection: 4 to 8 mg/dL</p>
          </list-item>
        </list>
        <p>
<bold>Once Daily Dosing Concentrations: </bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Monitor after the initial dose, no need to wait for four half-lives</p>
          </list-item>
          <list-item>
            <p>Clinicians can use the Hartford nomogram (multiply drug concentration scale by a factor of 2 to use) to estimate the appropriateness of the once-daily dosing (ODD) regimen.</p>
          </list-item>
          <list-item>
            <p>Recommend confirmatory trough concentration 30 min before the next scheduled dose if using the nomogram: less than 2.5 mg/dL (goal trough with ODD)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17456.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>No antidote for toxicity is available, only 20% dialyzable; however, this is variable based on hemodialysis filter. Avoid potentially toxic prolonged peak concentrations above 35 mcg/mL.</p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Clindamycin, chloramphenicol, and tetracycline can inactivate amikacin and other aminoglycosides.</p>
        <p>High-ceiling diuretics like furosemide increase ototoxicity and have the potential to increase the concentration of amikacin, thereby&#x000a0;worsening the ototoxicity.</p>
        <p>Other medications that can increase amikacin concentrations in the blood include NSAIDs (especially indomethacin) and quinidine.</p>
      </sec>
      <sec id="article-17456.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Amikacin is a beneficial drug to treat aerobic gram-negative&#x000a0;infections. Healthcare workers, including&#x000a0;the clinicians who prescribe it, should always check renal function regularly as the drug is nephrotoxic. In many inpatient facilities, the clinician or infectious disease specialist will initiate amikacin as part of the antimicrobial regimen and then allow the clinical pharmacist to handle dosing and subsequent dose adjustment. Nursing will perform drug administration and should have open access to both the clinicians and the pharmacists. If problems arise, the nurse or pharmacist must reach out to the clinician to adjust therapy. The interprofessional team, including&#x000a0;all clinicians, specialists, nurses, and pharmacists, should all be responsible for assessing treatment effectiveness and monitoring for side effects. [Level 5]</p>
      </sec>
      <sec id="article-17456.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17456&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17456">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17456/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17456">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17456.s11">
        <title>References</title>
        <ref id="article-17456.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Endo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nemoto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hanawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maebayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hasebe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naito</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Isobe</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Relationship between amikacin blood concentration and ototoxicity in low birth weight infants.</article-title>
            <source>J Infect Chemother</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-21</page-range>
            <pub-id pub-id-type="pmid">30539740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17456.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nolt</surname>
                <given-names>VD</given-names>
              </name>
              <name>
                <surname>Pijut</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Autry</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Arora</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kuhn</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Amikacin target achievement in adult cystic fibrosis patients utilizing Monte Carlo simulation.</article-title>
            <source>Pediatr Pulmonol</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-39</page-range>
            <pub-id pub-id-type="pmid">30507069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17456.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kulengowski</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Burgess</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Killing activity of meropenem in combination with amikacin against VIM- or KPC-producing Enterobacteriaceae that are susceptible, intermediate, or resistant to amikacin.</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>93</volume>
            <issue>4</issue>
            <fpage>372</fpage>
            <page-range>372-375</page-range>
            <pub-id pub-id-type="pmid">30514595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17456.r4">
          <label>4</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Block</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blanchard</surname>
                <given-names>DL</given-names>
              </name>
            </person-group>
            <chapter-title>Aminoglycosides</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">31082149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17456.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sturkenboom</surname>
                <given-names>MGG</given-names>
              </name>
              <name>
                <surname>Simbar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Akkerman</surname>
                <given-names>OW</given-names>
              </name>
              <name>
                <surname>Ghimire</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bolhuis</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Alffenaar</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Amikacin Dosing for MDR Tuberculosis: A Systematic Review to Establish or Revise the Current Recommended Dose for Tuberculosis Treatment.</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>Nov</month>
            <day>28</day>
            <volume>67</volume>
            <issue>suppl_3</issue>
            <fpage>S303</fpage>
            <page-range>S303-S307</page-range>
            <pub-id pub-id-type="pmid">30496466</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17456.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Illamola</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>HQ</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bhakta</surname>
                <given-names>ZN</given-names>
              </name>
              <name>
                <surname>Sherwin</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Liou</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Carveth</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Population Pharmacokinetics of Amikacin in Adult Patients with Cystic Fibrosis.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>62</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">30061295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17456.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Smits</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Renard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wead</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kagan</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Healy</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>De Cock</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Allegaert</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sherwin</surname>
                <given-names>CMT</given-names>
              </name>
            </person-group>
            <article-title>Impact of Disease on Amikacin Pharmacokinetics and Dosing in Children.</article-title>
            <source>Ther Drug Monit</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>44</fpage>
            <page-range>44-52</page-range>
            <pub-id pub-id-type="pmid">30299427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17456.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cooke</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Kon</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Dedicoat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Loyse</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chis Ster</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>TS</given-names>
              </name>
            </person-group>
            <article-title>Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>61</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">28696239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17456.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wrohan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Redwood</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Velen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2021</year>
            <month>Jan</month>
            <day>01</day>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-30</page-range>
            <pub-id pub-id-type="pmid">33384041</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
